Exhibit 99.1
REDWOOD CITY, Calif. and NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) — Amplitude Healthcare Acquisition Company (Nasdaq: AMHC) (“AMHC”), a particular goal acquisition firm, immediately introduced that its stockholders voted to approve the beforehand introduced enterprise mixture (the “Enterprise Mixture”) with Jasper Therapeutics, Inc. (“Jasper”), a biotechnology firm centered on the event of novel healing therapies primarily based on the biology of the hematopoietic stem cell, and all different proposals introduced at AMHC’’s particular shareholder’s assembly held on September 22, 2021.
AMHC’’s shareholders permitted the Enterprise Mixture proposal with 74.9% votes in favor of the roughly 9,872,643 AMHC votes solid on the assembly. AMHC plans to file the outcomes of the assembly, as tabulated by an impartial inspector of elections, on a Type 8-Ok with the Securities and Change Fee (the “SEC”).
Holders of 9,262,099 shares of AMHC Class A standard inventory have elected to redeem their shares in reference to the Enterprise Mixture. Because of such redemptions, Jasper has agreed to waive the requirement that the amount of money accessible in AMHC’s belief account following the Enterprise Mixture be, within the mixture, no less than $130.0 million.
Topic to the satisfaction or waiver of the opposite customary closing situations, the Enterprise Mixture is predicted to shut on or about September 24, 2021. Following the closing, the mixed firm will function as “Jasper Therapeutics, Inc.” and, on or about September 27, 2021, its shares of voting widespread inventory and warrants are anticipated to start buying and selling on the Nasdaq Capital Market.
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology firm centered on the event of novel healing therapies primarily based on the biology of the hematopoietic stem cell. The corporate is advancing two doubtlessly groundbreaking applications. JSP191, an anti-CD117 monoclonal antibody, is in scientific growth as a conditioning agent that clears hematopoietic stem cells from bone marrow in sufferers present process a hematopoietic cell transplantation. It’s designed to allow safer and more practical healing allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to beat key limitations of allogeneic and autologous gene-edited stem cell grafts. Each revolutionary applications have the potential to remodel the sphere and broaden hematopoietic stem cell remedy cures to a larger variety of sufferers with life-threatening cancers, genetic ailments and autoimmune ailments than is feasible immediately. For extra info, please go to us at jaspertherapeutics.com.
About Amplitude Healthcare Acquisition Company
Amplitude was based by Avego and Metalmark to hunt revolutionary personal life sciences firm acquisition targets. We leverage our administration and board’s fame, expertise, and observe report of constructing investments and creating worth within the business. We’ve got a robust historical past of constructing and rising corporations as constructive and reliable companions. For extra info, please go to: https://www.amplitudehealthcare.com.
Ahead-Wanting Statements
Sure statements included on this press launch that aren’t historic details are forward-looking statements for functions of the protected harbor provisions beneath america Personal Securities Litigation Reform Act of 1995. Ahead-looking statements are typically accompanied by phrases akin to “consider,” “might,” “will,” “estimate,” “proceed,” “anticipate,” “intend,” “anticipate,” “ought to,” “would,” “plan,” “predict,” “potential,” “appear,” “search,” “future,” “outlook” and comparable expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. These forward-looking statements embrace, however usually are not restricted to, statements concerning the proposed enterprise mixture between AMHC and Jasper Therapeutics, the estimated or anticipated future outcomes and advantages of the mixed firm following the enterprise mixture, together with the probability and talent of the events to efficiently consummate the enterprise mixture, the timing of the completion of the proposed enterprise mixture, Jasper Therapeutics’ enterprise technique, anticipated money sources of the mixed firm and the anticipated makes use of thereof, present and potential product candidates, deliberate scientific trials and preclinical actions and potential product approvals, in addition to the potential for market acceptance of any permitted merchandise and the associated market alternative. These statements are primarily based on numerous assumptions, whether or not or not recognized on this press launch, and on the present expectations of the respective administration groups of Jasper Therapeutics and AMHC and usually are not predictions of precise efficiency. These forward-looking statements are offered for illustrative functions solely and usually are not supposed to function, and should not be relied on by an investor as, a assure, an assurance, a prediction or a definitive assertion of truth or likelihood. Precise occasions and circumstances are tough or not possible to foretell and can differ from assumptions. Many precise occasions and circumstances are past the management of Jasper Therapeutics and AMHC. These forward-looking statements are topic to plenty of dangers and uncertainties, together with normal financial, political and enterprise situations; the shortcoming of the events to consummate the transactions or the prevalence of any occasion, change or different circumstances that would give rise to the termination of the enterprise mixture settlement; the failure of the PIPE financing to shut on the phrases and within the quantities at present anticipated; the result of any authorized proceedings that could be instituted towards the events following the announcement of the Enterprise Mixture; the chance that the potential product candidates that Jasper Therapeutics develops might not progress by means of scientific growth or obtain required regulatory approvals inside anticipated timelines or in any respect; dangers referring to uncertainty concerning the regulatory pathway for Jasper Therapeutics’ product candidates; the chance that scientific trials might not verify any security, efficiency or different product traits described or assumed on this press launch; the chance that Jasper Therapeutics can be unable to efficiently market or achieve market acceptance of its product candidates; the chance that Jasper Therapeutics’ product candidates will not be useful to sufferers or efficiently commercialized; the chance that Jasper Therapeutics has overestimated the scale of the goal affected person inhabitants, their willingness to attempt new therapies and the willingness of physicians to prescribe these therapies; the results of competitors on Jasper Therapeutics’ enterprise; the chance that third events on which Jasper Therapeutics relies upon for laboratory, scientific growth, manufacturing and different vital companies will fail to carry out satisfactorily; the chance that Jasper Therapeutics’ enterprise, operations, scientific growth plans and timelines, and provide chain may very well be adversely affected by the results of well being epidemics, together with the continuing COVID-19 pandemic; the chance that Jasper Therapeutics can be unable to acquire and preserve adequate mental property safety for its investigational merchandise or will infringe the mental property safety of others; the potential lack of ability of the events to efficiently or well timed consummate the proposed transaction; the chance of failure to comprehend the anticipated advantages of the proposed transaction and different dangers and uncertainties indicated on occasion in AMHC’s public filings, together with its most up-to-date Annual Report on Type 10-Ok for the 12 months ended December 31, 2020 and the proxy assertion/prospectus referring to the proposed transaction, together with these beneath “Danger Components” therein, and in AMHC’s different filings with the SEC. If any of those dangers materialize or AMHC’s and Jasper Therapeutics’ assumptions show incorrect, precise outcomes might differ materially from the outcomes implied by these forward-looking statements. There could also be further dangers that neither AMHC nor Jasper Therapeutics presently know, or that AMHC or Jasper Therapeutics at present consider are immaterial, that would additionally trigger precise outcomes to vary from these contained within the forward-looking statements. As well as, forward-looking statements replicate AMHC’s and Jasper Therapeutics’ expectations, plans or forecasts of future occasions and views as of the date of this press launch. AMHC and Jasper Therapeutics anticipate that subsequent occasions and developments will trigger AMHC’s and Jasper Therapeutics’ assessments to alter. Nonetheless, whereas AMHC and Jasper Therapeutics might elect to replace these forward-looking statements sooner or later sooner or later, AMHC and Jasper Therapeutics particularly disclaim any obligation to take action. These forward-looking statements shouldn’t be relied upon as representing AMHC’s and Jasper Therapeutics’ assessments of any date subsequent to the date of this press launch. Accordingly, undue reliance shouldn’t be positioned upon the forward-looking statements.
Contacts
Jasper Therapeutics Contacts
Lily Eng (media)
Actual Chemistry
206-661-8627
leng@realchemistry.com
Jeet Mahal (buyers)
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com
Amplitude Contact
IR@amplitudehealthcare.com
Robert Flamm, Ph.D. (media) / Harrison Wong (media)
212-213-0006
rflamm@burnsmc.com / hwong@burnsmc.com
Eric Ando (investor)
212-213-0006
eando@burnsmc.com
